Pharsight

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7973040	MERCK SHARP DOHME	Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors	Jul, 2029 (6 years from now)
US8871759	MERCK SHARP DOHME	Inhibitors of hepatitis C virus replication	May, 2031 (8 years from now)
CN102159285B	MERCK SHARP DOHME	Quinoxaline Compound As Hcv Ns3 Macrocyclic Protease Inhibitor	Jul, 2029 (6 years from now)
CN102159285A	MERCK SHARP DOHME	Macrocyclic Quinoxaline Compounds As Hcv Ns3 Protease Inhibitors	Jul, 2029 (6 years from now)
CN102427729B	MERCK SHARP DOHME	Inhibitor Of Hepatitis C Virus Replication	Mar, 2030 (7 years from now)
CN103880862A	MERCK SHARP DOHME	Inhibitor Of Hepatitis C Virus Replication	Mar, 2030 (7 years from now)
CN103880862B	MERCK SHARP DOHME	Inhibitors Of Hepatitis C Virus Replication	Mar, 2030 (7 years from now)
CN102427729A	MERCK SHARP DOHME	Inhibitor Of Hepatitis C Virus Replication	Mar, 2030 (7 years from now)
EP2540350A1	MERCK SHARP DOHME	Combinations Of A Macrocyclic Quinoxaline Compound Which Is An Hcv Ns3 Protease Inhibitor With Other Hcv Agents	Jul, 2029 (6 years from now)
EP2540349A1	MERCK SHARP DOHME	Pharmaceutical Compositions Comprising A Macrocyclic Quinoxaline Compound Which Is An Hcv Ns3 Protease Inhibitor	Jul, 2029 (6 years from now)
EP2540350B1	MERCK SHARP DOHME	Combinations Of A Macrocyclic Quinoxaline Compound Which Is An Hcv Ns3 Protease Inhibitor With Other Hcv Agents	Jul, 2029 (6 years from now)
EP2540349B1	MERCK SHARP DOHME	Pharmaceutical Compositions Comprising A Macrocyclic Quinoxaline Compound Which Is An Hcv Ns3 Protease Inhibitor	Jul, 2029 (6 years from now)
EP2310095B1	MERCK SHARP DOHME	Macrocyclic Quinoxaline Compounds As Hcv Ns3 Protease Inhibitors	Jul, 2029 (6 years from now)
EP2310095A1	MERCK SHARP DOHME	Macrocyclic Quinoxaline Compounds As Hcv Ns3 Protease Inhibitors	Jul, 2029 (6 years from now)
EP2410844B1	MERCK SHARP DOHME	Inhibitors Of Hepatitis C Virus Replication	Mar, 2030 (7 years from now)
EP2410844A4	MERCK SHARP DOHME	Inhibitors Of Hepatitis C Virus Replication	Mar, 2030 (7 years from now)
EP2410844A1	MERCK SHARP DOHME	Inhibitors Of Hepatitis C Virus Replication	Mar, 2030 (7 years from now)

Drugs and Companies using ELBASVIR; GRAZOPREVIR ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
50MG;100MG	TABLET;ORAL	Prescription

availability in other generic markets.

Click on the highlighted region to filter.